We have previously reported that inhibition ofhuman CFU-erythroid (E) colony formation by tumor necrosis factor (TNF) is an indirect effect mediated by a soluble factor released from a fraction of marrow accessory cells which are predominantly stromal elements (Means, R. T., Jr., E. N. Dessypris, and S. B. Krantz. 1990. J. Clin. Invest. 86:538-541). Further studies reported here identify a mediator of this effect.
Introduction
The anemia of chronic disease is one of the most common hematologic disorders in clinical medicine ( 1 ). Among the inflammatory cytokines which have been proposed as mediators of this syndrome is tumor necrosis factor (TNF)' (2, 3) . To understand the mechanism better by which TNF exerts its inhibitory effect on erythropoiesis, we studied its effect on in vitro colony formation by highly purified CFU-erythroid (E) generated from peripheral blood erythroid burst-forming units (4, 5) . We found that the inhibitory effect of TNF was indirect and mediated by a soluble factor released from marrow acces-sory cells (6) . These accessory cells resided in the marrow fraction precipitated by soybean agglutinin but were neither T lymphocytes nor monocytes.
We have continued our investigations into the inhibitory effect of TNF on CFU-E colony formation, and now report that this inhibitory effect requires the presence ofhuman ,3IFN, and that 3IFN itself exerts a direct inhibitory effect on CFU-E colony formation.
Methods
Blood and bone marrow were obtained from normal volunteers after informed consent. These studies were approved by the Vanderbilt University and Nashville Department of Veterans Affairs Medical Center Institutional Review Boards. Recombinant human TNFa (rTNF). rTNF (bioactivity 24 x 106 U / mg protein) was a generous gift from Dr. Abla Creasey, Cetus Corp., Emeryville, CA.
Human f3IFN. /3IFN (sp act 1.0 X 105 U/mg protein) was purchased from Lee Biomolecular Sciences, San Diego, CA.
Neutralizing antibodies. Specific neutralizing antibodies to human yIFN, TNF, and IL-l were purchased from Genzyme Corp., Boston MA. Neutralizing antibody specific for human (#IFN was purchased from Lee Biomolecular Sciences.
Purification of highly purified human CFU-E from peripheral blood. The method has been reported in detail by Sawada et al. (4, 5) . Briefly, 400 ml of heparinized blood from normal donors was separated over Ficoll-Hypaque (1.077 g/ml; Pharmacia Fine Chemicals, Picataway, NJ; Winthrop-Breon Laboratories, New York, NY) at 400 g for 25 min at 24°C. The light density mononuclear cells were collected in alpha MEM (Sigma Chemical Co., St. Louis, MO.), washed, and resuspended in Iscove's modified Dulbecco's medium (IMDM; Sigma Chemical Co.). T cells were depleted by sheep erythrocyte rosetting (4). Adherent cells were then depleted by overnight incubation in 75 cm2 polystyrene tissue culture flasks in IMDM with 20% FCS (Hyclone Laboratories, Logan, UT) and 4% giant cell tumor conditioned medium (CM; Gibco Laboratories, Grand Island, NY) at 37°C in a 5% CO2 atmosphere.
After overnight incubation, the nonadherent cells were collected in 37°C MEM and underwent negative panning with CDI lb/OKM*l, CD2/OKT*ll (Ortho Diagnostic Systems, Raritan, NJ), CD45/ Myl 1, and CD16/My23 as previously described (4), to remove colony-forming units granulocyte-macrophage, neutrophils, monocytes, lymphocytes, and natural killer cells. The remaining cells (typically 0.34% erythroid burst-forming units [4] ) were then cultured at a concentration of 3 X 105/ml in 0.9% methylcellulose (Fisher Scientific Co., Fairlawn, NJ) with 30% FCS, 1% deionized HSA (American Red Cross Blood Services, Washington, DC), l0-4 M 2-mercaptoethanol (Eastman Kodak Co., Rochester, NY), penicillin 500 U/ml, streptomycin 40 gg/ml, recombinant human insulin 10 U/ml (Eli Lilly Co., Indianapolis, IN), recombinant human IL-3 50 U/ml (Genetics Institute, Cambridge, MA), and recombinant human erythropoietin (Amgen Biologicals, Thousand Oaks, CA) 2 U/ml, in l-ml aliquots distributed into 12-well tissue culture plates (Limbro; Flow Laboratories, Inc., McLean, VA.) at 37°C in a high humidity 5% C02/95% air incubator.
After 7 d, the cells were collected in MEM. Debris and residual contaminating cells were then separated from highly purified CFU-E by centrifugation through 10% BSA (Armour Pharmaceutical Co., Kankakee, IL), followed by centrifugation over Ficoll-Hypaque, and adherence in plastic flasks with 20% FCS for 1 h at 370C. This process reproducibly yields a 94% viable population of day 8 peripheral blood cells, 30-90% of which are CFU-E (4, 5). The remaining 10-70% of cells are polymorphonuclear and basophilic leukocytes.
Marrow cell preparation. 6 ml of bone marrow was aspirated from the posterior iliac crest and collected in an equal volume of IMDM containing 5 U sodium heparin/ml. Marrow cells were then enriched for light density mononuclear cells (LDMN cells) by separation over Ficoll-Hypaque. In some experiments, marrow cells were depleted ofT lymphocytes and adherent cells as described for peripheral blood, above.
Preparation of conditioned medium. CM was prepared from LDMN marrow cells suspended in IMDM with 30% FCS at a concentration of 1 X 107 cells/ml and incubated at 370C for 48 h in plastic tissue culture flasks with rTNF 10-'0 M (TNFCM), as described previously (6). The cell suspension was collected and centrifuged at 400 g for 5 min to remove the cells. The cell-free supernatant was collected and stored at -20'C.
Culture of CFU-E in plasma clots. Peripheral blood or marrow CFU-E were cultured at concentrations of 103 peripheral blood day 8 cells (highly purified CFU-E)/ml or 0.5-2.0 x i0' marrow cells/ml with IMDM, 15% FCS, 15% pooled human AB serum, 0.25% HSA or BSA, recombinant erythropoietin 1 U/ml, penicillin, streptomycin, epsilon aminocaproic acid 1.5 mM, fibrinogen 1.3 mg/ml (Fibrinogen Kabi, grade L; Kabi Diagnostica, Stockholm, Sweden) and thrombin 0.2 U/ml (Parke-Davis Pharmaceuticals, Morris Plains, NJ)with varying concentrations of hu#IFN, TNFCM, and/or neutralizing antibodies to cytokines. In neutralizing antibody experiments, cells and culture medium were incubated with the antibody at 4VC for 1 h before the addition of rTNF or TNFCM. Cells were cultured for 7 d at 370C in 5% C02/95% air and then fixed and stained with benzidine-hematoxylin as described by McLeod et al. (7) . Human CFU-E were defined as colonies of 8-49 hemoglobinized cells (8) .
Each point was studied with three to six replicates, and results were normalized to the growth of control plasma clots (cultured without rTNF or TNFCM) so that results of different experiments might be compared. Statistical comparison was by ttest. Linear regression analysis was performed using a computer statistics program (Systat, Inc., Evanston, IL).
Assayfor,IFN. CM was assayed for the presence of hu#IFN using a commercially available ELISA kit purchased from Toray-Fuji Bionics, Inc., Tokyo, Japan.
Results
We previously reported that rTNF inhibited CFU-E colony formation by unpurified LDMN marrow cells (6) . To identify the mediator of this inhibitory effect, LDMN marrow cells were cultured in plasma clots with rTNF 1010 M and with neutralizing antibodies to various human cytokines (Table I) . The inhibitory effect of rTNF on CFU-E colony formation was completely ablated by neutralizing antibody to human f3IFN, but not by antibody to human yIFN or IL-1.
Although highly purified CFU-E colony formation is not inhibited by rTNF, TNFCM does have an inhibitory effect on these cells (6) . To confirm the role of,IFN in the inhibitory effect of TNF, highly purified CFU-E (mean purity 28.3%) were cultured with TNFCM in the presence or absence of neutralizing antibody to human ,3IFN (Table II) . Anti-,BIFN completely reverses the inhibitory effect of TNFCM.
While rTNF does not exert a direct inhibitory effect on Data from three experiments, using LDMN cells containing 0.49±0.10% CFU-E (98±20 CFU-E/plasma clot), are combined.
Results are expressed as mean±SE. * P < 0.03. colony formation by highly purified CFU-E, it is possible that rTNF may sensitize these cells to the effect ofa direct inhibitor or inhibitors present in TNFCM. To address this possibility, highly purified CFU-E (mean purity 21.7%) were cultured with TNFCM in the presence of neutralizing antibodies to human TNF. The inhibitory effect of TNFCM was not altered by anti-TNF (Table III) , indicating that the only role of rTNF in inhibition of CFU-E colony formation is to stimulate the release of a direct inhibitor.
If flIFN is a mediator of the inhibitory effect of TNF on CFU-E colony formation, the addition of this cytokine to plasma clots containing highly purified CFU-E should lead to decreased colony formation. flIFN inhibited colony formation by highly purified CFU-E (mean purity 21.0%) in a dose-dependent fashion (Fig. 1 ).
To determine whether the inhibitory effect of f3IFN is a direct effect, limiting dilution analysis was performed on highly purified CFU-E exposed to flIFN at a concentration of 1,000 U/ml (5, 9). Ifthe effect of,3IFN was indirect, the graph ofthe limiting dilution plot would be biphasic, with the line originally pointing away from the origin and then turning toward the origin as the CFU-E are diluted out. The points shown in Fig. 2 fall on a straight line passing though the origin (C.,, = -0.99),
indicating that the inhibitory effect of /IFN is the result of direct action on the CFU-E.
,BIFN also inhibits colony formation by CFU-E from unpurified marrow cells (Fig. 3) . As shown in the Fig. 3 , T lymphocyte or adherent cell depletion ofLDMN marrow cells does not significantly alter the degree of inhibition (P > 0.05 by linear regression analysis). If#IFN were the sole factor involved in the inhibitory effect of rTNF on CFU-E colony formation, then the concentration of fIFN present in TNFCM could be estimated by comparing the inhibitory effect produced by TNFCM to the ,BIFN dose response curve for highly purified CFU-E. These values indicate that 10% TNFCM decreases CFU-E colony formation to -52% of control (Tables II and III) , and a comparable effect would require -10-100 U/ml huBIFN (Fig. 1) . Thus, if /3IFN is the sole mediator of the inhibitory effect of TNF, then undiluted TNFCM should contain 100-1,000 U/ml flIFN. However, an ELISA specific for huflIFN (Toray-Fuji Bionics) indicated that flIFN concentration was < 2.5 U/ml. Therefore, huf3IFN, while required for the inhibitory effect of rTNF on CFU-E, is not the sole responsible factor, but acts in synergy with some other, as yet unidentified, factor or factors.
Discussion
In our previous study ofthe inhibitory effect of rTNF on CFU-E colony formation, we demonstrated that unpurified LDMN marrow cell colony formation was inhibited by rTNF, but no inhibitory effect was seen with highly purified CFU-E (6). We further demonstrated that this inhibition was mediated by a soluble factor or factors released from the soybean agglutininagglutinated fraction of marrow in response to rTNF (6) . The present report demonstrates that 3IFN is one of the factors required for this effect. It has previously been shown that I3IFN inhibits colony formation by marrow BFU-E (10), but no further work has been reported on the mechanism by which this inhibition occurs: whether it acts through other cytokines released from accessory cells, or by a direct effect on erythroid progenitor cells. In this report, we demonstrate that f3IFN inhibits colony formation by highly purified human CFU-E, that depletion ofaccessory cells does not alter ,3IFN's inhibitory effect on marrow CFU-E col- ony formation, and that ,3IFN inhibits CFU-E colony formation directly, as shown by limiting dilution analysis. We believe that this report also provides the first evidence suggesting a role for IIFN in the anemia associated with chronic inflammatory disease. As mentioned above, TNF is a proposed mediator ofthe anemia of chronic disease (2, 3, 1 1 ). This has been shown by the development ofa similar anemia in mice exposed to TNF (3) and in patients treated with TNF ( 12), as well as the demonstration of elevated serum TNF levels in patients with infectious and neoplastic diseases (13) . However, the mechanism ofthis effect has been unknown. The studies reported here demonstrate that, for human CFU-E in vitro, the inhibitory effect of TNF requires I3IFN.
Such an inhibitory role would be consistent with the reported effects of #IFN on cellular growth and differentiation.
,3IFN appears to inhibit growth stimulatory signaling pathways directly (14) , and appears to be involved in the natural suppression of immune proliferation in response to stimuli ( 15) . ( 17) . Superinduction of these cells with poly I-poly C led to the production of large quantities of ,IFN ( I03 U/ml) ( 17) . Castro-Malaspina et al. also studied marrow stromal cells in liquid culture and found that these cells gave rise to fibroblast colonies ( 18) . TNF has been shown to induce flIFN in fibroblasts (19, 20) , suggesting that these are the marrow cells ultimately responsible for the inhibitory effect of TNF on erythropoiesis.
Our previous report did not rule out the possibility that rTNF, while not the direct mediator of CFU-E inhibition, might sensitize these cells to a direct inhibitor (6) . The antibody studies presented above demonstrate that this is not the case (Table III) . However, the investigations reported here strongly indicate that rTNF induces some other factor (other than those tested in this study) which acts in either a synergistic or a cooperative manner with JIFN.
In conclusion, we have demonstrated that inhibition ofhuman CFU-E colony formation in vitro by TNF requires $IFN and that flIFN exerts a direct inhibitory effect on human CFU-E. Insufficient quantities of JIFN are present to be the sole mediator ofthis inhibition, indicating that ,BIFN acts in cooperation with other factors, as yet unidentified, to inhibit CFU-E colony formation. The source of J3IFN is not directly identified, but resides in a marrow stromal cell fraction that has been previously demonstrated to produce fIFN in response to induction ( 17, 19, 20) .
